Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 78

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 78
---
      637      1,006  

The Group has applied the practical
expedient permitted by IFRS 15 to not disclose the transaction price allocated to performance obligations unsatisfied (or partially unsatisfied)
as of the end of the reporting period as contracts typically have an original expected duration of a year or less.

Book values approximate to fair value
at 31 December 2024, 2023 and 2022.

Expected Credit
Loss

Given the short-term
nature of the Group’s trade receivables and accrued income, which are mainly due from large national or multinational companies,
the Group's assessment of expected credit losses includes provisions for specific clients and receivables where the contractual cash flow
is deemed at risk. Considerations include the current economic environment along with historical and forward-looking information. No assumptions
or estimating techniques are applied in considering these. Additional provisions are made based on the assessment of recoverability of
aged receivables over one year where sufficient evidence of recoverability is not evident.

Trade and other receivables
contained one impaired asset in 2024 and one in 2022. The asset from 2022 was written off in 2023. In 2023 Trade and other receivables
did not contain an impaired asset. The Group did hold security in 2022 as detailed below against the impaired asset.

The maximum exposure
to credit risk at the consolidated statement of financial position date is the fair value of each class of receivable.

The Company recognises
a default on a financial asset when the counter party announces they have limited resources to satisfy the debt.

14 Cash
and cash equivalents and cash flow supporting notes

Cash and cash equivalents for purposes
of the consolidated statement of cash flows comprises:

  Schedule of cash and cash equivalents                                                                    
                                             2024                  2023                  2022              
  Cash at bank available on demand                      1,669                 5,971                 2,836  

During 2024, 2023 and 2022, cash inflows
arose from equity financing transactions, included within financing activities on the face of the cash flow statement. As part of the
equity transactions entered in July and May 2024 and December and May 2023 warrants to the value of £3.1 million ( 2023:£4.6
million; 2022: £nil) were issued as disclosed in note 19.

  Schedule of cash inflows from an equity financing transaction